35.03.02 · health-medicine / chronic-disease

Cardiovascular disease: atherosclerosis, risk factors, myocardial infarction pathophysiology

stub3 tiersLean: nonepending prereqs

Anchor (Master): Ross, R. — Atherosclerosis — an inflammatory disease (1999)

Intuition Beginner

Cardiovascular disease kills more people than any other cause — about 18 million per year worldwide. The main process driving this toll is atherosclerosis, the slow buildup of fatty plaques inside artery walls. A plaque begins when the artery's inner lining is damaged by high blood pressure, smoking, or high blood sugar. Low-density lipoprotein — LDL, the "bad cholesterol" — seeps through the damaged lining, and white blood cells follow, igniting inflammation.

Over years the plaque grows — a cholesterol core sealed under a cap of fibrous tissue. Most heart attacks happen when that cap tears: blood rushes in, a clot forms, and the artery blocks. Without oxygen, the heart muscle fed by that artery begins to die. This is a myocardial infarction — an MI — and the damage becomes permanent after about twenty minutes.

The INTERHEART study, examining 15,000 heart attack patients across 52 countries, found that nine modifiable risk factors account for about 90 percent of all heart attack risk worldwide. Statins lower cholesterol and save lives; stents and bypass surgery reopen blocked arteries. Diet, exercise, and not smoking prevent most of the disease before it starts.

Visual Beginner

Plaque stage	What happens	Clinical meaning
Healthy artery	Smooth lining, unimpeded blood flow	No symptoms
Fatty streak	LDL enters wall, macrophages engulf it, foam cells form	Begins in childhood, silent
Fibrous plaque	Smooth muscle builds a cap over the lipid core	Gradual narrowing, stable angina
Vulnerable plaque	Thin cap, large lipid core, inflammatory cells	Rupture-prone, no warning
Plaque rupture	Cap tears, thrombus blocks the lumen	Heart attack or stroke

INTERHEART risk factor	Direction	Modifiable?
ApoB / ApoA1 ratio (dyslipidemia)	Higher ratio raises risk	Yes
Smoking	Current raises risk	Yes
Hypertension	Higher pressure raises risk	Yes
Diabetes	Presence raises risk	Partially
Abdominal obesity	Larger waist raises risk	Yes
Psychosocial stress	Higher stress raises risk	Partially
Fruit / vegetable intake	Lower intake raises risk	Yes
Physical activity	Lower activity raises risk	Yes
Alcohol	Regular moderate intake is protective	Yes

Worked example Beginner

How much does lowering cholesterol reduce risk?

Clinical trials have established a rule of thumb: every 1 mmol/L reduction in LDL cholesterol (about 39 mg/dL) lowers the risk of a major heart attack or stroke by about 22 percent.

A patient starts with an LDL of 160 mg/dL — well above the target of 70 mg/dL for high-risk patients. His doctor prescribes a statin. Three months later, his LDL is 80 mg/dL — a reduction of 80 mg/dL, or about 2 mmol/L.

The risk reduction compounds. Lowering LDL by 2 mmol/L means applying the 22 percent reduction twice: 0.78 times 0.78 = 0.61. His risk of a cardiovascular event falls by roughly 39 percent — close to 40 percent — even though his LDL only halved.

A patient who cuts LDL from 160 to 60 mg/dL — a drop of 100 mg/dL, or about 2.6 mmol/L — applies the 22 percent reduction 2.6 times: 0.78 raised to the power 2.6 is about 0.54, a 46 percent reduction in events.

What does this tell us? Small reductions in cholesterol compound into large reductions in risk. The benefit is large because the relationship between LDL and risk is exponential, not linear. Lower is better, and earlier is better — plaque builds for decades before symptoms appear.

Check your understanding Beginner

Exercise 1 (easy, multiple choice).

What event most commonly triggers an acute myocardial infarction?

A. Gradual narrowing of the artery until blood flow ceases

B. Rupture of an atherosclerotic plaque followed by thrombus formation

C. A sudden spike in blood pressure from emotional stress

D. A bacterial infection of the heart muscle

Hint

Think about whether most heart attacks come from slow, predictable narrowing or from a sudden structural failure of the plaque.

Answer

Option B. The majority of acute myocardial infarctions result from rupture or erosion of an atherosclerotic plaque, which exposes the thrombogenic lipid core to the bloodstream and triggers clot formation. Gradual narrowing (A) produces stable angina, not acute infarction. Stress (C) and infection (D) are not the usual proximate cause.

Formal definition Intermediate+

Cardiovascular disease (CVD) denotes the family of disorders of the heart and blood vessels whose common pathological substrate is atherosclerosis — coronary heart disease (myocardial infarction, angina), cerebrovascular disease (ischemic and hemorrhagic stroke), peripheral arterial disease, and aortic aneurysm. The formal treatment below follows Kumar, Abbas, Fausto and Aster, Robbins Basic Pathology (10th ed., 2021), Ch. 10 ^{[Ch. 10 The cardiovascular system]}.

Atherosclerosis: the response-to-injury cascade

Atherosclerosis is a chronic inflammatory disease of the arterial intima, initiated by endothelial injury and sustained by lipid accumulation and the innate immune response. Russell Ross formalized the response-to-injury hypothesis: the same noxious agents that injure the endothelium — hemodynamic stress at arterial branch points, hypertension, toxins from cigarette smoke, hyperglycemia (see 35.01.02, homeostasis and blood pressure regulation) — increase endothelial permeability to circulating lipoproteins.

Low-density lipoprotein (LDL) particles cross the injured endothelium and accumulate in the intima, where they undergo oxidation to oxLDL. Circulating monocytes adhere to activated endothelial cells (via VCAM-1 and ICAM-1), migrate into the intima, and differentiate into macrophages. Macrophages take up oxLDL through scavenger receptors (SR-A, CD36) — a pathway unregulated by feedback, since scavenger receptors do not downregulate in response to cellular cholesterol load. The lipid-laden macrophages become foam cells, whose accumulation forms the fatty streak, the earliest visible atherosclerotic lesion. Fatty streaks appear in the aorta in the first decade of life and are clinically silent.

The inflammatory cascade escalates: macrophages and endothelial cells secrete cytokines (IL-1, TNF- $α$ , MCP-1) that recruit additional monocytes and T lymphocytes. Smooth muscle cells migrate from the media into the intima (stimulated by PDGF) and proliferate, secreting collagen and elaborating a fibrous cap over the lipid-laden core. The plaque now consists of a necrotic core (dead foam cells, cholesterol crystals, extracellular lipid) covered by the fibrous cap. The American Heart Association classifies lesions from Type I (initial lesion, isolated foam cells) through Type VI (complicated lesion with surface defect, hematoma, or thrombosis).

Plaque vulnerability and rupture

Plaque stability depends on the balance between cap thickness and the mechanical and enzymatic forces acting on it. Vulnerable plaques (thin-cap fibroatheromas) have a large necrotic core, a thin fibrous cap ( $< 65 μ m$ ), heavy macrophage infiltration, and few smooth muscle cells. Macrophage-derived matrix metalloproteinases (MMPs) — collagenases, gelatinases — degrade the cap's collagen scaffold, weakening it to the point of rupture (see 17.01.*, molecular biology, extracellular matrix). When the cap tears, the thrombogenic core contacts blood: tissue factor activates the coagulation cascade, platelets adhere and aggregate, and a thrombus forms. If the thrombus is occlusive, the downstream tissue suffers infarction.

Myocardial infarction: the ischemic cascade

Myocardial infarction is defined by the Fourth Universal Definition (Thygesen et al., 2018) as evidence of myocardial injury (a rise and/or fall of cardiac troponin with at least one value above the 99th percentile) in a clinical setting consistent with myocardial ischemia. A type 1 MI results from atherothrombotic plaque disruption; a type 2 MI results from supply-demand imbalance without plaque disruption (tachyarrhythmia, hypotension, anemia).

The ischemic cascade proceeds in a characteristic sequence after coronary occlusion. Blood flow ceases; aerobic metabolism fails within seconds; the cell switches to anaerobic glycolysis, producing lactate and depleting ATP. ATP depletion disables membrane ion pumps: the sarcolemma becomes leaky, intracellular calcium rises, and membrane integrity fails. Irreversible injury — defined by mitochondrial swelling, membrane rupture, and coagulative necrosis — begins at approximately 20 minutes of total occlusion and progresses transmurally from subendocardium to subepicardium over the next 3–6 hours. The coronary anatomy determines the territory: occlusion of the left anterior descending artery (LAD, the "widow-maker") infarcts the anterior wall and interventricular septum; the left circumflex (LCX) supplies the lateral wall; the right coronary artery (RCA) supplies the inferior wall and, in a right-dominant circulation, the posterior septum and AV node (see 18.02.*, hemodynamics and the cardiac cycle).

Electrocardiography detects the injury current: ST-segment elevation in two contiguous leads defines STEMI (ST-elevation MI), signaling full-thickness (transmural) ischemia and warranting immediate reperfusion. Non-ST-elevation MI (NSTEMI) reflects subtotal occlusion or microvascular injury. Cardiac troponin I and T are the gold-standard biomarkers: they rise within 3–4 hours of injury, peak at 24 hours, and remain elevated for 7–10 days. Complications include ventricular arrhythmias (the leading cause of pre-hospital death), cardiogenic shock, papillary muscle rupture causing acute mitral regurgitation, ventricular septal rupture, and pericarditis (Dressler syndrome, a late autoimmune phenomenon).

Heart failure and stroke

Heart failure is the syndrome in which the heart cannot deliver adequate cardiac output to meet metabolic demand, or does so only at elevated filling pressures. In heart failure with reduced ejection fraction (HFrEF), systolic dysfunction — typically from prior MI, dilated cardiomyopathy, or volume overload — drops the ejection fraction below 40 percent. In heart failure with preserved ejection fraction (HFpEF), the ventricle is stiff and does not fill adequately; ejection fraction is normal but stroke volume is low. Both activate neurohormonal compensation — the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system — which become maladaptive, driving remodeling, fibrosis, and fluid retention (see 35.01.02, homeostatic failure).

Stroke is classified as ischemic (85 percent) or hemorrhagic (15 percent). Ischemic stroke results from in-situ thrombosis (carotid atherosclerosis) or embolism (atrial fibrillation, the leading cardioembolic source). Hemorrhagic stroke includes intracerebral hemorrhage (driven by chronic hypertension and amyloid angiopathy) and subarachnoid hemorrhage (ruptured saccular aneurysm). Treatment of ischemic stroke within the therapeutic window uses intravenous tissue plasminogen activator (tPA) or mechanical thrombectomy (see 18.05., nervous system; 29.02., neuroscience, brain regions).

Risk stratification models

The Framingham Risk Score estimates 10-year coronary heart disease probability from age, sex, total cholesterol, HDL, systolic blood pressure, smoking, and hypertension treatment. The ASCVD Pooled Cohort Equations generalize this to atherosclerotic cardiovascular disease (including stroke) and stratify by race, derived from multiple U.S. cohorts. The INTERHEART case-control study (Yusuf et al., 2004) established the nine modifiable risk factors — abnormal ApoB/ApoA1 ratio, smoking, hypertension, diabetes, abdominal obesity, psychosocial stress, low fruit and vegetable intake, physical inactivity, and alcohol — that account for approximately 90 percent of the population-attributable risk of MI globally (see 35.02.04, epidemiology, cohort studies and the Framingham Heart Study).

Key result: population attributable risk and the INTERHEART findings Intermediate+

The INTERHEART study quantified how much of the world's heart attack burden is explained by modifiable risk. The tool that converts a relative risk into a population-level burden is population attributable risk (PAR), and its derivation is short enough to present in full.

Derivation of the population attributable risk fraction

Let $P_{e}$ denote the prevalence of a risk factor in the population, and let $R R$ denote the relative risk of disease in exposed versus unexposed individuals. Write $I_{e}$ for the incidence among the exposed and $I_{u}$ for incidence among the unexposed, so $R R = I_{e} / I_{u}$ . The total disease incidence in the population is the prevalence-weighted average:

I_{pop} = P_{e} \cdot I_{e} + (1 - P_{e}) \cdot I_{u} .

The excess incidence — cases that would not have occurred absent the exposure — is $P_{e} (I_{e} - I_{u})$ . The attributable fraction is the ratio of excess to total:

P A R % = \frac{P _{e} ( I _{e} - I _{u} )}{P _{e} \cdot I _{e} + ( 1 - P _{e} ) \cdot I _{u}} \times 100.

Substituting $I_{e} = R R \cdot I_{u}$ and dividing numerator and denominator by $I_{u}$ :

P A R % = \frac{P _{e} ( R R - 1 )}{P _{e} \cdot R R + ( 1 - P _{e} )} \times 100 = \frac{P _{e} ( R R - 1 )}{P _{e} ( R R - 1 ) + 1} \times 100.

The final form shows that PAR depends on only two quantities: how common the risk factor is ( $P_{e}$ ) and how strongly it increases risk ( $R R$ ). A rare exposure with high RR can have low PAR; a common exposure with modest RR can have high PAR.

Application: INTERHEART's nine factors

INTERHEART enrolled 15,152 first-MI cases and 14,820 controls across 52 countries and computed the odds ratio (approximating RR under the rare-disease assumption; see 35.02.04) for each factor. Smoking carried an odds ratio of about 2.9; the ApoB/ApoA1 ratio (top vs. bottom quintile) about 3.3; psychosocial stress about 2.5. Applying the PAR formula to each factor individually and combining them multiplicatively, the nine factors collectively accounted for 90 percent of PAR in men and 94 percent in women — a result consistent across geographic regions, ethnic groups, and income levels.

The nontrivial implication is that the majority of myocardial infarction risk worldwide is explained by factors that are, in principle, modifiable. This does not mean they are easily modified — psychosocial stress, food environments, and addiction are shaped by socioeconomic forces beyond individual control (see 30.04.*, sociology, stratification; 30.08.03, urban sociology). But it identifies the targets: the INTERHEART framing reframes cardiovascular disease from an inevitable consequence of aging into a condition whose dominant determinants are known and, collectively, addressable.

The LDL log-linear relationship

A second quantitative result governs treatment. The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis of statin trials established that each 1 mmol/L reduction in LDL cholesterol reduces the relative risk of a major vascular event by approximately 22 percent, independent of baseline LDL. If $Δ L$ is the LDL reduction in mmol/L, the residual relative risk is:

R R_{residual} = 0.7 8^{Δ L},

a log-linear (exponential) dose-response. This is the quantitative basis for aggressive LDL targets ( $< 70$ mg/dL in high-risk patients) and for combination therapy with statins, ezetimibe, and PCSK9 inhibitors. The exponential form also explains why a statin that halves LDL (a 50 percent reduction in absolute terms) can reduce events by 40 percent or more — the benefit compounds with the magnitude of reduction ^{[Atherosclerosis and coronary artery disease]}.

Exercises Intermediate+

Exercise 2 (easy, multiple choice).

In the universal definition of myocardial infarction, a type 1 MI is caused by:

A. Supply-demand mismatch from tachycardia and anemia

B. Atherothrombotic plaque disruption with intraluminal thrombus

C. Coronary artery spasm (Prinzmetal angina)

D. Cardiac catheterization-related myocardial injury

Hint

The five universal MI types are distinguished by mechanism. Type 1 is the classic plaque-rupture event; type 2 is demand ischemia; types 4 and 5 are procedure-related.

Answer

Option B. A type 1 MI results from atherosclerotic plaque disruption (rupture or erosion) with intraluminal thrombus formation. This is the archetypal heart attack. Type 2 MI (A) reflects supply-demand mismatch. Prinzmetal angina (C) is vasospastic and may cause MI but is not the type 1 mechanism. Procedure-related injury (D) corresponds to type 4 or 5.

Exercise 3 (medium, short answer).

Explain the response-to-injury hypothesis of atherosclerosis. Name three agents that can cause the initial endothelial injury and describe the cellular sequence from LDL infiltration to fibrous cap formation.

Hint

Structure the answer in stages: (1) what injures the endothelium, (2) what enters through the injured barrier, (3) which immune cells respond, (4) what the smooth muscle does in response.

Answer

The response-to-injury hypothesis (Ross, refined 1999) holds that atherosclerosis begins with endothelial dysfunction caused by hemodynamic stress at branch points, hypertension, cigarette smoke toxins, or hyperglycemia. The injured endothelium becomes permeable to LDL, which enters the intima and undergoes oxidation to oxLDL. Circulating monocytes adhere to the activated endothelium (via VCAM-1), migrate into the intima, and differentiate into macrophages that phagocytose oxLDL through scavenger receptors, becoming lipid-laden foam cells — the fatty streak. Macrophages and endothelial cells release cytokines (IL-1, TNF- $α$ , MCP-1) that recruit more monocytes and T cells. Platelet-derived growth factor (PDGF) stimulates smooth muscle cells to migrate from the media into the intima, proliferate, and secrete the collagen-rich extracellular matrix that constitutes the fibrous cap over the necrotic lipid core.

Exercise 5 (medium, short answer).

A 62-year-old man presents with 90 minutes of crushing substernal chest pain radiating to the left arm, diaphoresis, and nausea. His ECG shows 3 mm ST elevation in leads V2–V4. Name the diagnosis, the likely occluded coronary artery, and the target door-to-balloon time. Explain why rapid reperfusion changes the clinical outcome.

Hint

ST elevation in V2–V4 points to a specific coronary territory. The 20-minute threshold for irreversible injury and the transmural progression of necrosis determine why time matters.

Answer

Diagnosis: Acute anterior STEMI (ST-elevation myocardial infarction). Occluded artery: The left anterior descending artery (LAD), which supplies the anterior wall and interventricular septum — the territory represented by leads V2–V4. Door-to-balloon target: $\leq 90$ minutes from hospital arrival to percutaneous coronary intervention (PCI), the standard of care for STEMI when PCI is available within 120 minutes of first medical contact.

Irreversible myocardial injury begins after approximately 20 minutes of total occlusion and progresses transmurally from subendocardium to subepicardium over 3–6 hours. Each additional minute of occlusion kills more myocytes — the clinical aphorism is "time is muscle." Myocytes do not regenerate appreciably in adults; infarcted tissue is replaced by collagenous scar, permanently reducing contractile function. Restoring flow before irreversible necrosis sets in salvages myocardium, preserves ejection fraction, and reduces the risks of arrhythmia, heart failure, and death.

Exercise 6 (hard, numeric).

Three independent risk factors have the following prevalences and relative risks for MI:

Factor	Prevalence $P_{e}$	Relative risk $R R$
A	0.30	3.0
B	0.20	4.0
C	0.25	2.0

(a) Compute the individual $P A R %$ for each factor. (b) Assuming the three factors act independently, estimate the combined PAR using the product formula:

P A R_{combined} = 1 - i \prod (1 - P A R_{i}) .

Express all answers as percentages rounded to one decimal place. (c) What does the combined result imply about the proportion of MI risk that remains unexplained?

Hint

For each factor compute $P_{e} (R R - 1) / [P_{e} (R R - 1) + 1]$ . Then multiply the complements $(1 - P A R_{i})$ and subtract from 1.

Answer

(a) Individual PARs:

Factor A: $0.30 \times 2/ (0.60 + 1) = 0.60/1.60 = 0.375$ , so $P A R_{A} = 37.5%$ .
Factor B: $0.20 \times 3/ (0.60 + 1) = 0.60/1.60 = 0.375$ , so $P A R_{B} = 37.5%$ .
Factor C: $0.25 \times 1/ (0.25 + 1) = 0.25/1.25 = 0.200$ , so $P A R_{C} = 20.0%$ .

(b) Combined PAR (independent action):

P A R_{combined} = 1 - (1 - 0.375) (1 - 0.375) (1 - 0.200)

= 1 - (0.625) (0.625) (0.800) = 1 - 0.3125 = 0.6875,

so $P A R_{combined} = 68.8%$ .

(c) The three factors collectively explain about 68.8 percent of MI incidence in this population. The remaining 31.2 percent is attributable to unmeasured factors, genetic predisposition, interactions between measured factors (the independence assumption likely overstates the combined PAR if factors are correlated), and stochastic events. This mirrors the structure of the INTERHEART result: a handful of factors explains the majority but not all of disease burden.

Exercise 7 (hard, short answer).

The CANTOS trial (Ridker et al., 2017) randomized 10,061 patients with prior MI and elevated high-sensitivity CRP to canakinumab (an anti-IL-1 $β$ monoclonal antibody) or placebo. Canakinumab reduced cardiovascular events by approximately 15 percent with no change in LDL cholesterol. Explain why this result is considered evidence that inflammation is a causal driver of atherosclerosis, not merely a marker. What would the result have implied had canakinumab reduced both CRP and LDL?

Hint

Consider the distinction between an observational correlation (CRP is elevated in patients who have events) and an interventional test (blocking IL-1 $β$ reduces events). The key is what variable changed and what did not.

Answer

Elevated CRP (C-reactive protein) is an observational marker of cardiovascular risk, but observational correlation cannot establish causation: CRP might be elevated because it tracks with another causal factor (obesity, infection, subclinical atherosclerosis) rather than because the inflammation it reflects drives disease. CANTOS addressed this by intervening on the causal pathway: canakinumab blocks IL-1 $β$ , a proximal cytokine in the inflammatory cascade, thereby reducing downstream inflammation (and CRP) without altering lipids. Because LDL cholesterol was unchanged between groups, the observed 15 percent reduction in cardiovascular events cannot be attributed to lipid lowering — it must reflect the anti-inflammatory effect. This satisfies a Bradford Hill "experiment" criterion for the inflammatory pathway as a cause, not merely a correlate, of cardiovascular events.

Had canakinumab reduced both CRP and LDL, the trial would have been uninformative about the independent role of inflammation: the event reduction could have been driven entirely by the lipid change, and the two effects could not be disentangled. The design — intervening on inflammation while holding lipids constant — is what made the causal inference possible.

Advanced results Master

Inflammation as a therapeutic target

Russell Ross's 1999 reframing of atherosclerosis as an inflammatory disease ^{[N. Engl. J. Med. 340 (1999) 115-126]} generated a therapeutic prediction: if inflammation drives plaque progression independently of cholesterol, then targeted anti-inflammatory therapy should reduce cardiovascular events without lowering LDL. The CANTOS trial (Ridker et al., 2017) tested this with canakinumab, a monoclonal antibody against interleukin-1 $β$ (IL-1 $β$ ), in 10,061 patients with prior MI and elevated high-sensitivity CRP. Canakinumab reduced the composite cardiovascular endpoint by approximately 15 percent with no change in LDL, establishing the inflammatory pathway as a modifiable causal contributor — the first demonstration that an intervention unrelated to lipids could reduce hard cardiovascular outcomes. The result opened a class of anti-atherosclerotic targets distinct from statins: colchicine (the COLCOT trial), IL-6 signaling, and NLRP3 inflammasome components (see 17.07.*, signaling, inflammation; 35.02.02, bacterial pathogenesis, endotoxin, TLRs, innate immunity).

C-reactive protein remains a debated biomarker. Elevated high-sensitivity CRP predicts cardiovascular events in healthy populations (Ridker's JUPITER trial enrolled patients with normal LDL but elevated CRP and showed statin benefit), but whether CRP is itself causal or merely a downstream marker of systemic inflammation is unresolved. The CANTOS result — reducing inflammation reduced events while CRP fell modestly — supports the view that the upstream cytokine cascade (IL-1 $β \to$ IL-6 $\to$ CRP), not CRP itself, is the therapeutic target.

The lipid hypothesis: from Anitschkow to PCSK9

The lipid hypothesis — that elevated circulating cholesterol drives atherosclerosis — traces to Nikolai Anitschkow's 1913 cholesterol-feeding experiments in rabbits and was contested for decades. Observational epidemiology (the Framingham Study, 1948; the Seven Countries Study, Ancel Keys, 1958; see 35.02.04, epidemiology; 35.04.*, nutrition, the Mediterranean diet) established cholesterol as a risk factor, but the causal inference required intervention. The statin era settled the question: the 4S trial (1994) showed simvastatin reduced total mortality by 30 percent in patients with established coronary disease; WOSCOPS (1995), CARE (1996), and LIPID (1998) extended the benefit to broader populations. The Cholesterol Treatment Trialists' meta-analyses confirmed a log-linear relationship — roughly 22 percent event reduction per 1 mmol/L LDL lowering — that holds across baseline LDL levels, statin vs. non-statin agents, and primary vs. secondary prevention.

The discovery of PCSK9 inhibitors deepened the lipid paradigm. PCSK9 (proprotein convertase subtilisin/kexin type 9) degrades the hepatic LDL receptor; loss-of-function mutations in PCSK9 produce lifelong low LDL and dramatically reduced cardiovascular risk (a natural experiment consistent with Mendelian randomization). Monoclonal antibodies against PCSK9 — evolocumab, alirocumab — lower LDL by 50–60 percent on top of statins and reduce cardiovascular events (FOURIER, ODYSSEY OUTCOMES). The pharmacogenomics of statin response illustrates the precision-medicine frontier: the SLCO1B1 variant increases simvastatin-induced myopathy risk, and dosing can be adjusted accordingly (see 35.08., precision medicine, pharmacogenomics; 33.04., chemistry revolution, lipid chemistry).

Social determinants and the cardiovascular gradient

Michael Marmot's Whitehall studies of British civil servants (1978 onward) demonstrated a steep social gradient in cardiovascular mortality across employment grades, persisting after adjustment for smoking, blood pressure, and cholesterol. The gradient — present even within a population with universal health care — points to psychosocial mechanisms: low control at work, effort-reward imbalance, and chronic stress activation of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system, with downstream inflammation, endothelial dysfunction, and metabolic dysregulation (see 29.11.03, stress and health, allostatic load; 30.04.02, class structure, class and health).

INTERHEART formalized psychosocial stress as a global cardiovascular risk factor, and the U.S. Black-White disparity in cardiovascular disease — Black Americans have higher hypertension prevalence, earlier onset, and worse outcomes — has been analyzed through Arline Geronimus's weathering hypothesis: chronic exposure to structural racism accelerates physiological wear, measurable as earlier onset of cardiovascular and metabolic disease (see 30.04.03, race and ethnicity). Neighborhood-level determinants — food deserts, low walkability, air pollution — compound individual-level risk and are themselves products of residential segregation and disinvestment (see 30.08.03, urban sociology, neighborhood effects). The PAR of social conditions on cardiovascular disease is nontrivial and exceeds that of many traditional clinical risk factors when measured at population scale.

Cardiovascular imaging

The diagnostic and prognostic armamentarium spans modalities tied to distinct physical principles. Echocardiography uses ultrasound to assess chamber size, wall motion, valve function, and ejection fraction — the workhorse of cardiac evaluation (see 29.03.03, auditory, ultrasound). Coronary angiography, the gold standard for luminal obstruction, requires cardiac catheterization: a contrast agent is injected into the coronary ostia and imaged under fluoroscopy. CT coronary calcium scoring detects calcified plaque by X-ray attenuation and stratifies risk noninvasively (see 28.06.02, X-ray imaging). Cardiac MRI characterizes myocardial tissue — scar, edema, infiltration — using late gadolinium enhancement and T1/T2 mapping (see 33.05., quantum revolution, nuclear magnetic resonance). Nuclear imaging (SPECT, PET) quantifies myocardial perfusion and viability using radiotracers (see 33.05., nuclear medicine). Each modality answers a different question: anatomy (angiography, CT), function (echo), tissue characterization (MRI), and perfusion (PET/SPECT).

Cardiovascular disease in global context

Ischemic heart disease is the leading cause of death worldwide, and the epidemiological transition — the shift from infectious to chronic disease as the dominant mortality driver — places cardiovascular disease at the center of global health (see 35.02.04, epidemiology; 30.07.03, global inequality). Low- and middle-income countries face a double burden: persisting infectious disease alongside rapidly rising cardiovascular mortality, driven by urbanization, dietary transition, tobacco marketing, and aging. Access to statins, PCI, and cardiac surgery is distributed inequitably.

Two infectious etiologies of cardiovascular disease anchor the global picture. Rheumatic heart disease — valve damage following group A streptococcal infection (see 35.02.02, bacterial pathogenesis) — has nearly disappeared in high-income countries with antibiotic access but remains common in resource-limited settings. Chagas cardiomyopathy, caused by Trypanosoma cruzi infection (see 35.02.01, infectious disease, parasitic), is a leading cause of heart failure in Latin America, where an estimated 6–7 million people are infected. The concentration of both diseases in impoverished populations is a case study in structural violence — the way economic and political arrangements distribute disease along lines of power (see 31.06.02, medical anthropology, structural violence, Farmer).

The frontier: regeneration, genomics, and digital health

Adult cardiomyocytes have limited regenerative capacity — the heart heals by scarring, not by replacing lost muscle — which has made regenerative cardiology a persistent goal. Stem-cell trials for cardiac repair have produced inconsistent results, and the mechanism (direct myocyte differentiation vs. paracrine signaling) remains debated. Polygenic risk scores for coronary artery disease (Khera et al., 2018) can identify individuals at 3-fold inherited risk who are invisible to traditional risk factors, though clinical integration and equity of access remain open problems (see 35.08.03, precision medicine, AI). Left ventricular assist devices (LVADs) and cardiac transplantation serve end-stage heart failure; the artificial heart remains an engineering aspiration. Wearable devices — the Apple Watch ECG, continuous blood pressure monitors — extend surveillance into the home and raise questions about data privacy, overdiagnosis, and the medicalization of normal physiological variation (see 33.07., computing, IoT; 36., media literacy, data privacy).

Connections Master

Homeostasis, hemodynamics, and the vessel wall

Cardiovascular disease is homeostatic failure of the blood pressure and flow regulatory loops. Hypertension is sustained set-point elevation that injures the endothelium and drives atherosclerosis; heart failure is the maladaptive neurohormonal response — RAAS and sympathetic activation — to reduced cardiac output. The hemodynamics of the cardiac cycle, Poiseuille flow in vessels, and the coupling of pressure, flow, and wall stress provide the mechanical substrate on which atherosclerosis develops preferentially at branch points and curvatures (35.01.02, homeostasis; 18.02.*, hemodynamics, blood flow and the vessel wall, cardiac cycle).

Epidemiology and the Framingham paradigm

The methodology of cardiovascular risk factor identification — the prospective cohort, the multivariate risk score, the population attributable fraction — is the methodology of chronic-disease epidemiology as developed in Framingham and applied worldwide. The INTERHEART case-control design and the Mendelian randomization approach to lipid causation are extensions of this framework (35.02.04, epidemiology, cohort studies, Framingham Heart Study, case-control design, Mendelian randomization).

Molecular biology of the extracellular matrix and plaque rupture

Plaque rupture is a failure of tissue mechanics: the fibrous cap's collagen, deposited by smooth muscle cells, is degraded by macrophage-derived matrix metalloproteinases. The balance of synthesis and degradation — the dynamics of collagen turnover in the arterial wall — links plaque vulnerability to the molecular cell biology of the extracellular matrix (17.01.*, molecular biology, extracellular matrix).

Inflammation, signaling, and innate immunity

Atherosclerosis is sustained by innate immune signaling: TLR4 activation by oxLDL, NLRP3 inflammasome assembly, IL-1 $β$ and IL-6 release, and the cytokine cascade that recruits monocytes and drives plaque progression. The CANTOS trial — pharmacologically blocking IL-1 $β$ — established this pathway as causally relevant, not merely correlated. The same signaling architecture appears in infection-driven inflammation and in the metabolic inflammation of obesity (17.07.*, signaling, inflammation; 35.02.02, bacterial pathogenesis, endotoxin, TLRs; 35.01.02, homeostatic failure).

Pharmacology of cardiovascular therapy

The drug classes that treat cardiovascular disease — statins (HMG-CoA reductase inhibitors), ACE inhibitors and ARBs (RAAS blockade), beta-blockers (sympathetic blockade), antiplatelet agents (aspirin, P2Y12 inhibitors), anticoagulants, and SGLT2 inhibitors — each target a specific node in the pathophysiology. Their mechanisms, evidence bases, and adverse-effect profiles are the substance of cardiovascular pharmacology (35.07.*, pharmacology, drug classes; 29.10.03, biological treatments, pharmacotherapy).

Stress, allostasis, and the social gradient

Chronic stress — via the HPA axis, sympathetic tone, and systemic inflammation — is a cardiovascular risk factor measured operationally as allostatic load. The Whitehall studies and INTERHEART establish that psychosocial stress is not a soft variable but a physiological exposure with measurable cardiovascular consequences. The social gradient in cardiovascular mortality — steeper in more unequal societies — places cardiovascular disease within the sociology of stratification (29.11.03, stress and health, allostatic load; 30.04.*, sociology, stratification; 30.04.02, class structure; 30.04.03, race and ethnicity, weathering hypothesis; 30.08.03, urban sociology, neighborhood effects).

Nutrition, metabolism, and the Mediterranean diet

Diet shapes cardiovascular risk through LDL (saturated fat), blood pressure (sodium), glycemic load (refined carbohydrate), and the anti-inflammatory profile of specific patterns. The PREDIMED trial established the Mediterranean diet as evidence-based primary prevention; the Seven Countries Study linked dietary fat to coronary disease. Cardiovascular nutrition is inseparable from the global food system and the economics of food access (35.04., nutrition; 33.04., chemistry revolution, lipid chemistry).

Medical anthropology and structural violence

The concentration of rheumatic heart disease and Chagas cardiomyopathy in impoverished populations is the pattern Paul Farmer named structural violence: disease distribution following lines of economic and political power. Cardiovascular disease, often framed in high-income contexts as a lifestyle condition, is in global context inseparable from the structural determinants that distribute risk and care (31.06.02, medical anthropology, structural violence, Farmer; 30.07.03, global inequality).

Precision medicine, systems biology, and reductionism

Polygenic risk scores, pharmacogenomics (SLCO1B1 and statin myopathy), and PCSK9-targeted therapy extend cardiovascular medicine toward individualized prediction and treatment. The systems-biology perspective — modeling the heart as a coupled multi-scale system from ion channels to hemodynamics — complements the reductionist approach and raises the question of when integrative modeling succeeds where single-mechanism explanations fail (35.08.*, precision medicine; 35.08.02, genomic medicine; 35.08.03, pharmacogenomics; 20.05.04, reductionism in biology, systems approach).

Downstream link to cancer biology

Chronic inflammation — the shared substrate of atherosclerosis — is also a hallmark of cancer. The same cytokine cascades that drive plaque progression (IL-1 $β$ , IL-6, TNF- $α$ ) promote tumor promotion, angiogenesis, and immune evasion. Smoking, obesity, and diabetes are risk factors for both cardiovascular disease and several cancers, and statin use has been associated with reduced cancer incidence in some (contested) studies. This overlap is the basis for the proposed link to the cancer-biology unit (35.03.03).

Historical and philosophical context Master

Anitschkow and the cholesterol-fed rabbit (1913)

Nikolai Anitschkow, working at the Military Medical Academy in Saint Petersburg with S. Chalatow, demonstrated that feeding rabbits a cholesterol-rich diet produced arterial lesions that histologically resembled human atherosclerosis. The 1913 experiments — "Über experimentelle Cholesterinsteatose" — established the first experimental link between cholesterol and arterial disease. The reception was skeptical: rabbits are herbivores whose cholesterol metabolism differs from that of humans, and dogs, rats, and other species failed to develop similar lesions on the same diet. Critics argued that the rabbit atherosclerosis was an artifact of a herbivore fed an unnatural diet. It was not until the second half of the twentieth century — with the identification of the LDL receptor by Joseph Goldstein and Michael Brown (Nobel Prize, 1985), the Framingham cohort data on cholesterol as a risk factor, and the statin trials showing that lowering cholesterol reduced disease — that Anitschkow's insight was recognized as having identified a genuine mechanism. Brown and Goldstein's receptor-mediated endocytosis pathway explained why LDL accumulates when receptors are deficient or saturated, providing the molecular mechanism that Anitschkow's macroscopic pathology had foreshadowed.

The Framingham Heart Study and the coinage of "risk factor" (1948–)

The Framingham Heart Study enrolled its first 5,209 residents of Framingham, Massachusetts, in 1948 under Thomas Dawber of the U.S. Public Health Service. The design — a prospective cohort following a defined community for decades, measuring physiological variables in healthy individuals before disease onset — had no precedent at this scale for a chronic disease. Before Framingham, the concept of a "risk factor" for a chronic disease did not exist in its modern form. In a 1961 paper in the Annals of Internal Medicine, William Kannel and colleagues coined the term and demonstrated that elevated blood pressure, elevated serum cholesterol, and the electrocardiographic sign of left ventricular hypertrophy each independently predicted subsequent coronary heart disease. The study introduced multivariate risk prediction — the estimation of individual risk from a combination of factors — and produced the Framingham Risk Score, whose descendants (the ASCVD Pooled Cohort Equations) remain in clinical use. The Framingham design was replicated worldwide: the Seven Countries Study, the Nurses' Health Study, the British Regional Heart Study, and the UK Biobank all follow the model of prospective data collection on healthy populations, generating the evidence base for the chronic-disease risk factor framework (see 35.02.04, epidemiology, the Framingham Heart Study as a landmark cohort).

Russell Ross and the inflammatory hypothesis (1999)

Russell Ross, a pathologist at the University of Washington, proposed with Donald Dzau and John Glomset in the early 1970s that atherosclerosis begins with endothelial injury — a "response to injury" hypothesis that challenged the prevailing view of atherosclerosis as a passive lipid storage disease. Over the following decades, Ross accumulated evidence that monocytes, macrophages, T lymphocytes, and the cytokines they produce are not incidental bystanders but active drivers of plaque formation and progression. His 1999 review in the New England Journal of Medicine, "Atherosclerosis — an Inflammatory Disease," consolidated this evidence and reframed the field ^{[N. Engl. J. Med. 340 (1999) 115-126]}. The reframing carried a therapeutic prediction that the lipid-only model did not: if inflammation drives atherosclerosis independently of cholesterol, then anti-inflammatory therapy should reduce cardiovascular events without altering lipid levels. The prediction was confirmed eighteen years later by the CANTOS trial, in which canakinumab — an antibody targeting IL-1 $β$ in the inflammatory cascade — reduced events with no change in LDL.

The statin revolution and the confirmation of the lipid hypothesis (1994)

The Scandinavian Simvastatin Survival Study (4S), published in the Lancet in 1994, was the first trial to demonstrate that lowering cholesterol with an HMG-CoA reductase inhibitor reduced total mortality. 4,444 patients with established coronary heart disease and elevated cholesterol were randomized to simvastatin or placebo; over a median follow-up of 5.4 years, simvastatin reduced total mortality by 30 percent and major coronary events by 34 percent. WOSCOPS (1995) extended the benefit to primary prevention in men with hypercholesterolemia but no prior infarction. These trials settled the long debate over whether cholesterol was a causal agent or a passive marker: lowering it, by inhibiting its hepatic synthesis, reduced disease and saved lives. The subsequent development of ezetimibe (intestinal cholesterol absorption inhibitor) and PCSK9 inhibitors (which increase LDL receptor recycling) confirmed that the benefit tracks LDL reduction regardless of the pharmacological mechanism — a consistency that supports a causal interpretation under the Bradford Hill criterion of coherence and the Mendelian randomization logic applied to PCSK9 loss-of-function variants.

Bibliography Master

Ross, R. (1999). "Atherosclerosis — an inflammatory disease." New England Journal of Medicine, 340(2), 115–126.
Yusuf, S., Hawken, S., Ôunpuu, S. et al. (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study." Lancet, 364(9438), 937–952.
Libby, P., Bonow, R. O., Mann, D. L., Zipes, D. P. & Braunwald, E. (Eds.) (2022). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (12th ed.). Elsevier.
Kumar, V., Abbas, A. K., Fausto, N. & Aster, J. C. (2021). Robbins Basic Pathology (10th ed.). Elsevier.
Anitschkow, N. & Chalatow, S. (1913). "Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse." Centralblatt für allgemeine Pathologie und pathologische Anatomie, 24, 1–9.
Dawber, T. R., Meadors, G. F. & Moore, F. E. (1951). "Epidemiological approaches to heart disease: the Framingham Study." American Journal of Public Health, 41(3), 279–286.
Kannel, W. B., Dawber, T. R., Kagan, A., Revotskie, N. & Stokes, J. (1961). "Factors of risk in the development of coronary heart disease — six-year follow-up experience: the Framingham Study." Annals of Internal Medicine, 55(1), 33–50.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). (1994). Lancet, 344(8934), 1383–1389.
Ridker, P. M., Everett, B. M., Thuren, T. et al. (2017). "Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS)." New England Journal of Medicine, 377(12), 1119–1131.
Thygesen, K., Alpert, J. S., Jaffe, A. S. et al. (2018). "Fourth universal definition of myocardial infarction." Journal of the American College of Cardiology, 72(18), 2231–2264.

Prerequisites

35.03.01 pending

Used in

35.03.03

Tier anchors

beginner: Kumar, V. et al. — Robbins Basic Pathology, 10th ed. (2021)
intermediate: Libby, P. et al. — Braunwald's Heart Disease, 12th ed. (2022)
master: Ross, R. — Atherosclerosis — an inflammatory disease (1999)

References

Kumar, V., Abbas, A. K., Fausto, N. & Aster, J. C. — Robbins Basic Pathology, 10th ed. (Elsevier, 2021) · Ch. 10 The cardiovascular system
Libby, P. et al. — Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 12th ed. (Elsevier, 2022) · Atherosclerosis and coronary artery disease
Ross, R. — Atherosclerosis — an inflammatory disease · N. Engl. J. Med. 340 (1999) 115-126; response to injury hypothesis
INTERHEART Study — Yusuf et al. (2004) · Lancet 364 (2004) 937-952; global risk factors for MI

Estimated time

beginner: 15m
intermediate: 30m
master: 45m